Keegan Sarah, Rose Jeremy H, Khan Zohra, Liebel Francois-Xavier
Department of Small Animal Medicine, Langford Veterinary Services, Langford, UK.
Neurology and Neurosurgery Service, Fitzpatrick Referrals, Godalming, UK.
Vet Rec Open. 2019 Feb 27;6(1):e000315. doi: 10.1136/vetreco-2018-000315. eCollection 2019.
Cytosine arabinoside (CA) and prednisolone are drugs commonly used together in the management of canine non-infectious meningoencephalitis (NIME). The aim of this study was to report the haematological findings before and after CA and prednisolone treatment and identify any adverse haematological events in this clinical setting, following the veterinary cooperative oncology group established common terminology criteria for recording adverse events following administration of chemotherapy or biological antineoplastic therapy.
While 48 patients with a presumptive diagnosis of NIME had pretreatment haematology results, only 12 patients met the inclusion criteria of also having post-treatment haematology results available for review after being treated with prednisolone and CA at a standard dose (200 mg/m) in a single referral hospital in the UK. Forty-nine post-treatment haematology results were available for these 12 patients.
Four adverse haematological events were identified in four patients. None of these events were convincingly attributable to CA administration.
阿糖胞苷(CA)和泼尼松龙是犬非感染性脑膜脑炎(NIME)治疗中常用的联合药物。本研究的目的是报告CA和泼尼松龙治疗前后的血液学检查结果,并根据兽医肿瘤协作组制定的化疗或生物抗肿瘤治疗后不良事件记录通用术语标准,确定在这种临床情况下的任何不良血液学事件。
虽然48例疑似NIME患者有治疗前血液学检查结果,但在英国一家转诊医院,只有12例患者符合纳入标准,即接受标准剂量(200mg/m)的泼尼松龙和CA治疗后也有治疗后血液学检查结果可供复查。这12例患者有49份治疗后血液学检查结果。
在4例患者中发现了4起不良血液学事件。这些事件均不能令人信服地归因于CA给药。